The September 11 PDUFA date for Pixclara is the next major binary catalyst. Continued revenue momentum and cash generation support the raised guidance range. Monitor SEC subpoena developments, though no charges have been asserted. The successful bond refinancing reduces interest cost and extends maturity.
Drugs in focus
TLX drug pipeline →TLX591-Tx
● Neutral Named in this 6-K- Impact
- Phase
- Phase 3
- Time to market
- Likely 2028+ (Phase 3 Part 2 enrollment underway, followed by event-driven rPFS readout, then regulatory filing)
- Next catalyst
- None dated
What to watchWatch for enrollment completion updates on ProstACT Global Part 2 and any interim rPFS data. The stock is heavily influenced by Illuccix/Gozellix revenue execution, so TLX591-Tx is a pipeline upside option, not the core thesis today. Near-term catalysts center on Telix's imaging franchise (Pixclara PDUFA) rather than this therapeutic.
- ● Zircaix 4/10 Phase 3 (ZIRCON) completed; BLA under FDA review Named in filing
- ▲ Gozellix 3/10 Approved (FDA, March 21, 2025 — NDA 219592, 505(b)(2)) Named in filing
- ● TLX101-Tx 3/10 Phase 3 (pivotal, just initiated); Phase 1 safety stage complete Named in filing
- ◆ ITM-11 4/10 Phase 3 (completed)
- All TLX drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 20 $12.42entry
- T+1 · 3mo ago −8.78%α −9.19% · $11.33
- T+5 · 3mo ago −8.41%α −9.53% · $11.38
- T+20 · 2mo ago +0.68%α +0.68% · $12.51
- T+60 · 4d ago −24.64%α −23.80% · $9.36
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Telix reported a strong H1 2026 with revenue of $477.4M (+22% YoY), swinging to a net profit of $38.3M from a -$2.3M loss, driven by Precision Medicine growth ($388.6M, +27%) and a $40M Regeneron collaboration payment. The company raised FY 2026 revenue guidance to the upper end of $950M-$970M range and increased R&D investment 52% to $123.8M. Key catalysts include a PDUFA date of September 11, 2026 for Pixclara (TLX101-Px) and progress across multiple late-stage therapeutic programs.
Key Facts
- Revenue from contracts with customers was $477.4M for H1 2026, up 22% from $390.4M in H1 2025.
- Net profit after tax was $38.3M, compared to a loss of $2.3M in H1 2025.
- Precision Medicine segment revenue grew 27% to $388.6M, with gross margin improving to 65%.
- Adjusted EBITDA was $51.9M, up 148% from $21.1M in H1 2025.
- R&D costs increased 52% to $123.8M, focused on late-stage therapeutic pipeline and regulatory filings.
- Cash and cash equivalents were $251.9M as of June 30, 2026, up from $141.9M at Dec 31, 2025.
- The company completed a debt refinancing: issued $600M 1.50% Convertible Notes due 2031 and repurchased ~98% of existing 2.375% bonds due 2029.
- FY 2026 revenue guidance raised to upper end of $950M-$970M range, excluding the $40M Regeneron payment.
- Pixclara (TLX101-Px) NDA resubmission accepted by FDA with PDUFA date of September 11, 2026.
- The company received a subpoena from the SEC and is subject to a securities class action; both in early stages.
Financial Impact
Revenue growth of $87.0M (+22%), net profit swing of $40.6M vs prior loss, Adjusted EBITDA more than doubled to $51.9M.
Risk Factors
- SEC subpoena and securities class action litigation are unresolved and could escalate.
- Pixclara and Zircaix regulatory decisions carry binary risk.
- The $40M Regeneron payment is non-recurring; core operating profit excluding this item was ~$6M.
- R&D spending is increasing rapidly (52% YoY) and may pressure margins.
- Foreign exchange translation losses of $30.1M reduced total comprehensive income.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001628280-26-058126 |
| Document: a20260820telixhy26append.htm | 0001628280-26-058126 |
| Document: tlx-20260630.htm | 0001628280-26-058126 |
| Document: presentation.htm | 0001628280-26-058126 |
Track record
27 reports on TLX
10 of 20 bullish or bearish reports moved the stock their way by T+1. Best: +29.26% at T+20 after the Jun 1, 2026 report. 18 of 20 went positive at some point.
Filters
- Oct 29, 202618d ago 6-K Neutral 5/10 Entry $9.10 to $9.05 Now $8.92 −1.98% ▼ −0.55% −0.07% vs SPY
- Oct 20, 202627d ago 6-K Neutral 4/10 No price data
- Oct 20, 202627d ago Press Release Bullish 6/10 Entry $10.03 to $9.54 Now $8.92 −11.07% ▼ −4.89% −3.70% vs SPY
- Sep 29, 20266w ago 6-K Bullish 6/10 Entry $10.97 to $10.72 Now $8.92 −18.69% ▼ −2.28% −2.46% vs SPY
- Sep 21, 20268w ago 6-K Bullish 7/10 Entry $11.31 to $11.95 Now $8.92 −21.13% ▲ +5.66% +5.67% vs SPY
- Sep 20, 20268w ago Press Release Bullish 7/10 Entry $11.31 to $11.95 Now $8.92 −21.13% ▲ +5.66% +5.67% vs SPY
- Sep 14, 20269w ago 6-K Bullish 8/10 Entry $12.83 to $11.83 Now $8.92 −30.48% ▼ −7.79% −7.35% vs SPY
- Sep 14, 20269w ago Press Release Bullish 8/10 Entry $11.78 to $12.83 Now $8.92 −24.28% ▲ +8.91% +9.37% vs SPY
- Sep 1, 202610w ago 6-K Bullish 7/10 Entry $11.45 to $11.74 Now $8.92 −22.10% ▲ +2.53% +1.49% vs SPY
- Sep 1, 202610w ago Press Release Bullish 6/10 Entry $11.45 to $11.74 Now $8.92 −22.10% ▲ +2.53% +1.49% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers